Shots:

• The Positive Opinion was adopted on Alirocumab on patients (n=153) with Heterozygous Familial Hypercholesterolemia
• The P-III study primary objective evaluate the safety & efficacy of Alirocumab that were every Q2W & every Q4W vs PBO for 24 wks., whereas the secondary objective includes effects on LDL-C levels, other lipid parameters & to evaluate safety & tolerability after open-label treatment, additionally analysis of anti-alirocumab antibodies
• Praluent, which comes in 2 dosages (75 mg & 150 mg), is the first and only PCSK9 inhibitor authorized in the US which blocks PCSK9 from binding to LDLR & decreases blood levels of LDL-Cl and increases the number of LDLRs available to remove LDL

Ref: European Medicines Agency | Image: Sanofi

*Note: This is not an original PR, this reference is taken based on European Medicines Agency website

Related News:- Sanofi and Regeneron Finalizes the Restructuring of Their Collaboration on Praluent (alirocumab)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com